Oculis Holding AG
Close on Oct 19, 2026
About Oculis
Pharmaceutical Preparations, SIC 2834
Oculis Holding AG operates as a clinical-stage biopharmaceutical organization engaged in the discovery, research, and development of pharmaceutical product candidates. The enterprise conducts preclinical evaluations, clinical trials, and regulatory compliance activities to advance medical treatments based on its scientific technology and in-licensed assets. It focuses on advancing a pipeline of candidate therapies toward commercial readiness and manufacturing. The company's intended recipients and end users include patient groups with targeted therapeutic needs, while its direct commercial relationships involve academic institutions, healthcare entities, and corporate research partners.
The enterprise is headquartered in Zug, Switzerland, where its principal executive offices are situated. Its geographic presence and operating footprint include facilities and corporate activities located across Switzerland, Iceland, and the United States. Additionally, the organization conducts cooperative scientific work through research and licensing partnerships with external international institutions.
Summary of the business section of Oculis's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Oculis Holding AG
- Headquarters
- Zug, V8
- Address
- Bahnhofstrasse 7 6300
- Phone
- (617) 937-2423
- Employees
- 60, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- V8
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers SA, Lausanne, Switzerland
Stock & identifiers
- Ticker
- OCS
- Other tickers
- OCSAW
- Exchange
- Nasdaq
- IPO date
- Jun 2, 2023
- Shares outstanding
- 60M, Dec 31, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1953530
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
Oculis's leadership is listed in its proxy statement (Form DEF 14A).
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 60 employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 2, 2023 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 1, 2023 | Listing | Registration of securities on an exchange (Form 8-A) |
| Nov 7, 2022 | Merger | Registration of securities for a merger or exchange offer (S-4) |